Concert Pharmaceuticals is a clinical stage biopharmaceutical company applying its knowledge of deuterium chemistry to discover and develop novel small molecule drugs. Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. The Company's approach typically starts with approved drugs that may be improved with deuterium substitution. Concert Pharmaceuticals's technology provides the opportunity to develop products that may compete with the non-deuterated drug in existing markets or to leverage the known activity of approved drugs to expand into new indications. The Company's deuterated chemical entity platform, or DCE Platform, has broad potential across numerous therapeutic areas.

Lexington, US
Size (employees)
69 (est)
Concert Pharmaceuticals was founded in 2006 and is headquartered in Lexington, US
Report incorrect company information

Key People/Management at Concert Pharmaceuticals

Roger Tung

Roger Tung

Founder, President, CEO & Board of Directors
Nancy Stuart

Nancy Stuart

Lynette Herscha

Lynette Herscha

General Counsel
James Cassella

James Cassella

Chief Development Officer

Concert Pharmaceuticals Office Locations

Concert Pharmaceuticals has an office in Lexington
Lexington, US (HQ)
500 99 Hayden Ave
Show all (1)
Report incorrect company information

Concert Pharmaceuticals Financials and Metrics

Concert Pharmaceuticals Financials

Market capitalization (5-Mar-2018)

534.9 m
Concert Pharmaceuticals's current market capitalization is $534.9 m.
Show all financial metrics
Report incorrect company information